Casirivimab + imdevimab

Generic name
Casirivimab + imdevimab
Brand name
ATC Code
J06BD07
Compare …

Casirivimab + imdevimab

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Pre-exposure prophylaxis COVID-19
  • Intravenous
    • ≥ 12 years and ≥ 40 kg

      • 600 mg/ 600 mg casirivimab / Imdevimab once. Then as needed 300 mg/ 300 mg casirivimab / imdevimab 1x every 4 weeks until prophylaxis is no longer needed.

         

      • If intravenous administration is not possible, subcutaneous administration may be considered. 

    • ≥ 12 years and ≥ 40 kg

      • 600 mg/ 600 mg casirivimab / Imdevimab once. Then as needed 300 mg/ 300 mg casirivimab / imdevimab 1x every 4 weeks until prophylaxis is no longer needed.

         

      • If intravenous administration is not possible, subcutaneous administration may be considered. 
Post-exposure prophylaxis COVID-19
  • Intravenous
    • ≥ 12 years and ≥ 40 kg
      [1]

      • 600 mg/ 600 mg casirivimab / imdevimab once as soon as possible after contact with an infected person.

      • If intravenous administration is not possible, subcutaneous administration may be considered. 

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

IMMUNOGLOBULINS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Immunoglobulins, normal human
J06BA02
J06BA01
Specific immunoglobulins
J06BB01
J06BB04
J06BB02
J06BB03
Antibacterial monoclonal antibodies
J06BC03
IMMUNOGLOBULINS, NORMAL HUMAN
J06BA02
J06BA01
Antiviral monoclonal antibodies
J06BD08
J06BD01

Reference

  1. Roche Registration GmbH, SmPC Ronapreve (EU/1/21/1601/001) 19-11-2021, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose